Background: Conflicting recommendations exist addressing the management of di-
| Extraction procedure
Use of an antibacterial mouthwash twice daily for 7 days prior to dental extraction was recommended but not mandated. Patients requiring infective endocarditis prophylaxis received a single dose of oral amoxicillin 2 g or clindamycin 600 mg 1 hour before extraction.
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Local anesthesia was achieved by local infiltration and/or regional anesthetic blocks using 2% lidocaine with 1:80 000 epinephrine. 
| Bleeding outcomes
The weight difference in gauze before and after biting was measured to estimate immediate blood loss. Phone calls were made to patients 2 and 7 days after extraction to ascertain bleeding complications.
Patients were also requested to contact the study dentist if they developed any bleeding.
Bleeding episodes were categorized as major according to the
International Society on Thrombosis and Haemostasis definition,
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with the additional definition of bleeding that threatened the airway. Clinically relevant nonmajor bleeding (CRNMB) was defined as bleeding that required medical intervention by a health care provider including oral anticoagulant discontinuation, bleeding that led to hospitalization or increased level of care without requiring surgical intervention, and bleeding that led to face-to-face evaluation. All other bleeds were categorized as minor.
| Laboratory assays
Blood samples were taken 30 to 60 minutes before extraction.
All hemostasis testing was performed on STAR instrumentation (Diagnostica Stago, Parsippany, NJ, USA). INR was measured using Stago reagent. Dabigatran level was measured by dilute thrombin time using commercial reagents (Hemoclot; Hyphen BioMed, Neuville-sur-Oise, France). Apixaban and rivaroxaban levels were measured by chromogenic anti-Xa assays using STA drug-specific calibrators and STA reagents. DOAC predicted on-therapy ranges used at Westmead Hospital are based on published literature and are adopted from the University of Washington Anticoagulation Services website. Mouthwash use prior to dental extraction, n (%) 6 (29) 29/85 (34)
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TA B L E 1 Patient and procedural characteristics
Preextraction antibiotic use, n (%) 3 (14) 10 (12) Extraction of posterior teeth compared to anterior teeth only, n (%)
16 (76) 60 (70) Gingival bleeding on probing, c n (%) 11/18 (61) 33/66 (50)
Surgical extraction compared to simple extraction, n (%) 2 (10) 15 (17) Achievement of primary closure, n (%) 11 (52) 20 (23) Abbreviations: AF, atrial fibrillation; BMI, body mass index; CrCl, creatinine clearance; LQ, lower quartile; NA, not applicable; UQ, upper quartile; VTE, venous thromboembolism. a Nonperiodontitis indications include deep caries and cracked tooth.
b Higher dose = apixaban 5 mg twice a day, dabigatran 150 mg twice a day, rivaroxaban 20 mg daily.
Lower dose = apixaban 2.5 mg twice a day, dabigatran 110 mg twice a day, rivaroxaban 15 mg daily. Other (dosing outside the approved dosing regimen) = daily dosing of apixaban/dabigatran, alternate-day rivaroxaban. c Bleeding on probing is an indication of active gingival inflammation.
INRs on the day of procedure and therefore were excluded from the study. Two patients on a DOAC were excluded due to inadvertent omission of their last dose.
In the majority of patients (82%), hemostasis was achieved within the 30-minute observation period immediately after extraction. The weight change in gauze used to apply pressure to the socket was comparable between the 2 groups (weight change of gauze per tooth, for sex, number of teeth extracted, and primary closure rates was 0.90 (95% CI, 0.14-5.80). Five (6%) patients on a DOAC experienced CRNMB at median 3 days after extraction (range, 0-7), namely, bleeding that required resuturing (n = 2), temporary DOAC cessation (n = 2), and dental clinic review (n = 2). All CRNMB were successfully managed with local hemostatic measures and temporary DOAC cessation in 2 patients.
Bleeding rates between the DOAC types were comparable, as summarized in Table 3 (apixaban, 39%; rivaroxaban, 37%; dabigatran 27%). Preextraction apixaban and dabigatran levels were similar between the bleeders and nonbleeders, while rivaroxaban levels were approximately 2-fold higher in those who bled (Table 3 ). Most of the rivaroxaban patients who bled had ingested rivaroxaban the morning of the extraction (82%; 95% CI, 52.3-94.9), compared to 18% (95% CI,
TA B L E 2 7-day bleeding outcomes
Bleeding event Warfarin n = 21
DOAC n = 86
Minor only, n (%) (95% CI) with an INR between 3 and 4 had a minor bleed after extraction.
Preextraction DOAC levels varied greatly. Six patients had a DOAC level outside the predicted on-therapy range: 2 (2%) lower, and 4 (5%) higher than predicted levels. The patient with a low apixaban level (23 ng/mL) did not experience any bleeding, while the patient with a low dabigatran level (17 ng/mL) developed a CRNMB on day 0 despite initially achieving complete hemostasis within the 30-minute observation period. The 4 patients with higher-than-predicted levels were all on rivaroxaban 20 mg daily (436, 470, 487, 581 ng/mL), only 1 of whom had a minor bleed.
Although conclusive associations cannot be made given the small sample size, bleeding in the DOAC users tended to occur after extraction of posterior teeth (81% vs. 64%) and surgical extraction (26% vs. 13%) ( Table 4) body mass index, renal function, time from last DOAC ingestion, and DOAC dose.
In this study, continuing DOACs at the time of teeth extractions led to bleeding rates similar to patients on warfarin who had an INR between 2.0 and 4.0, adding further evidence to the growing literature recommending DOAC continuation for dental extractions. 7, 9, 10, 15 The majority of the bleeding episodes were minor "nuisance" bleeds, with only 6% of DOAC patients developing a CRNMB in the 7 days following dental extractions. Therefore, timing dental extractions to avoid peak concentrations 7, 16 or targeting trough concentrations 17 is unlikely to provide any additional clinical benefit. Omitting DOAC doses 18 places the patient at undue risk for thromboembolism, yet upon DOAC recommencement, the patient will again be at risk of bleeding.
In this study, there was no "safe lower limit" of DOAC drug level below which dental extractions may be performed without postextraction bleeding. Therefore, we do not recommend measuring DOAC drug levels prior to dental extractions to predict bleeding outcomes.
Our findings support the current practice of standardized perioperative DOAC management based on the drug's pharmacokinetic properties and type of surgical procedure, rather than drug levels. 19, 20 We recognize that this study has a number of limitations. First, as the sample size of each cohort was limited to the eligible patients who presented to our department and provided informed consent, sample size calculations were not performed. Second, the number of patients was relatively small, particularly for those on warfarin.
Despite our best efforts, recruiting patients on warfarin was difficult due to few patients on warfarin presenting to our hospital with the need for dental extractions. In addition, several warfarin patients had to be excluded from the study due to unexpected subtherapeutic INRs on the day of the procedure. Third, patients were on various DOAC dosing regimens, which may have influenced outcomes.
Fourth, given that this study was not randomized, results may have been affected by residual confounding.
In conclusion, dental extractions incorporating local hemostatic measures was just as safe for patients continuing their usual DOAC dosing regimen as it was for patients on warfarin with a therapeutic INR. Our results suggest that there is no need to adjust DOAC dosing prior to dental extractions, nor is there a need to time the dental extractions around DOAC doses. DOACs and warfarin can be safely continued for simple or surgical dental extractions, eliminating the thrombotic risk associated with anticoagulant interruption.
